Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.Although many may claim they are specialists in conducting TQT studies, few have the data to back this up. Our published data shows that over the past decade, Richmond Pharmacology�s studies have consistently produced less variability of QT measurements when compared directly with our competitors. This confirms that we are the leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.At Richmond Pharmacology our mantra is good data in equals good data out.Our 10th Birthday PromiseWe are so confident and proud of our 100% success rate in TQT studies that should we fail to show assay sensitivity we will repeat the study at no cost to our sponsors.To take us up on our promise, contact our Business Development team today to discuss your TQT study needs

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event